| Press releases

Formycon signs term sheet for development of FYB202 and executes capital increase

Formycon plans to enter into a co-investment arrangement for its biosimilar candidate FYB202 and aims for a participation of up to 30% in worldwide marketing proceeds.


German Equity Forum

November 27-29, 2017; Frankfurt/Germany

Financial reports

Annual Report 2016

Published on:
May 3, 2017

  • Teaser_mitglied-bio-deutschland-en
  • Forschungssiegel_Teaser_Webseite-en
  • Teaser_mitglied-biosimilar-medicines-en
  • teaser-powerlist
  • teaser-wachstumschampion-en
  • pipeline-en-teaser
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out.